Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Genomic analysis reveals insights into pathogenesis of neuroblastoma
Key clinical point: A comprehensive genomic analysis has revealed novel insights into the pathogenesis of neuroblastoma.
Major finding: The most common gene alterations were MYCN (19%), TERT (17%), SHANK2 (13%), PTPRD (11%), ALK (10%), and ATRX (8%).
Study details: An integrated genomic analysis of 702 neuroblastoma tumor samples.
Disclosures: The study was supported by grants from the National Cancer Institute and by the American Lebanese Syrian Associated Charities of St. Jude Children’s Research Hospital. One author disclosed financial affiliations with Y-mabs Therapeutics, Abpro-Labs, Eureka Therapeutics, and Biotec Pharmacon.
Brady SW et al. Nat Commun. 2020 Oct 14. doi: 10.1038/s41467-020-18987-4.